Related Experiment Video
Updated: Jul 13, 2026
15:43
Assessment of Mitochondrial Functions and Cell Viability in Renal Cells Overexpressing Protein Kinase C Isozymes
Published on: January 7, 2013
Methylprednisolone reduces the nephrotoxicity caused by cisplatin
1Department of Urology, Faculty of Medicine, Kyushu University, Fukuoka, Japan.
Journal of Pharmacobio-Dynamics
|December 1, 1992
Summary
Methylprednisolone protects against cisplatin-induced kidney damage in rats. This finding suggests higher cisplatin doses may be safely used in cancer chemotherapy when combined with methylprednisolone.
Area of Science:
- Nephrology
- Pharmacology
- Oncology
Background:
- Cisplatin is a widely used chemotherapy agent.
- Cisplatin administration can cause significant kidney damage (nephrotoxicity).
- Methylprednisolone is a corticosteroid with anti-inflammatory properties.
Purpose of the Study:
- To investigate the protective effects of methylprednisolone against cisplatin-induced nephrotoxicity in a rat model.
- To determine the efficacy of varying methylprednisolone doses in mitigating cisplatin's kidney toxicity.
Main Methods:
- Male Sprague-Dawley rats received intravenous cisplatin at 6.5 or 8.5 mg/kg.
- Rats were co-administered subcutaneous methylprednisolone (50, 100, or 250 mg/kg) at -4, 0, and 4 hours relative to cisplatin.
- Blood urea nitrogen and serum creatinine levels were assessed on day 5 post-cisplatin administration.
Main Results:
- Methylprednisolone demonstrated clear protective effects against cisplatin-induced nephrotoxicity.
- Reduced levels of blood urea nitrogen and serum creatinine were observed in rats treated with methylprednisolone.
Conclusions:
- Methylprednisolone effectively mitigates cisplatin-induced kidney damage in this preclinical model.
- These findings support the potential for using higher cisplatin doses in chemotherapy when co-administered with methylprednisolone.
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates these...
01:25Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
01:26Kidney Transplant II: Surgical Procedure
Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living donor...
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...